Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease – Eli Lilly and Company

Written by

admin

in

  1. Lilly’s Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease  Eli Lilly and Company
  2. Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity  CNBC
  3. Lilly’s Mounjaro succeeds in cardiovascular outcomes trial, heads for expanded approval  Endpoints News
  4. Lilly’s Mounjaro Cuts Risk of Heart Attacks, Strokes in Study  Bloomberg.com
  5. Eli Lilly’s SURPASS-CVOT Study: A Potential Game-Changer in Diabetes Care  TipRanks

Continue Reading

More posts